Advances in engineering of low molecular weight hydrogels for chemotherapeutic applications

Biomed Mater. 2021 Feb 21;16(2):024102. doi: 10.1088/1748-605X/abdce1.

Abstract

Chemotherapy is the primary option for the treatment of cancer, inflammation, and infectious diseases. Conventional drug delivery poses solubility and bioavailability challenges, systemic toxicity, non-specific targeting, and poor accumulation of chemotherapeutic drugs at the desired site. Nanotechnology has led to the development of various nanomaterials that have decreased the toxicity and increased the accumulation of drugs at the target site. Systemic administration of nanomaterials causes burst release and non-specific targeting of chemotherapeutics, leading to off-target organ toxicity. Drug delivery based on low molecular weight hydrogels (LMWHs) provides a suitable alternative for drug delivery due to their ability to entrap chemotherapeutic drugs. Injectable and biodegradable LMWHs allow the administration of chemotherapeutics with minimal invasion, allow the sustained release of chemotherapeutic drugs for long periods, and reduce the challenges of immunogenicity and low drug entrapment efficiency. Herein, we summarize the advances in the engineering of LMWHs for controlled and prolonged delivery of chemotherapeutics for cancer, infectious diseases, and inflammatory disorders.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / chemistry*
  • Antineoplastic Agents / pharmacology*
  • Chemistry, Pharmaceutical / methods
  • Drug Carriers
  • Drug Delivery Systems
  • Heparin, Low-Molecular-Weight / therapeutic use
  • Humans
  • Hydrogels / chemistry*
  • Inflammation
  • Materials Testing
  • Mice
  • Molecular Weight
  • Neoplasms / drug therapy*
  • Neoplasms / metabolism
  • Protein Engineering / methods*
  • Tissue Engineering / methods*

Substances

  • Antineoplastic Agents
  • Drug Carriers
  • Heparin, Low-Molecular-Weight
  • Hydrogels